Adaptimmune Therapeutics (ADAP) : positive data on experimental cell therapy

• The company said that trials of its SPEAR T-cell therapy showed a 50% response rate in patients with synovial sarcoma. The company also reported confirmed responses in lung cancer patients, and had previously reported confirmed responses in head and neck cancer patients. 

 

Adaptimmune Therapeutics presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting

New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy.

Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US in 2022.

Phase 2 trial combining ADP-A2M4 with pembrolizumab in head and neck cancer (SPEARHEAD-2) will be the first time a SPEAR T-cell therapy is used in sequence with first line systemic therapy.

The company also announced new responses in the SURPASS trial, confirming the potential for SPEAR T-cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. These data further support the rationale for two new Phase 2 trials -- SPEARHEAD-2 in head and neck cancer, which will begin later this year, and a second trial in esophagogastric junction (EGJ) cancer planned for 1H 2021.

The SURPASS trial (a Phase 1 trial with ADP-A2M4CD8) will focus on lung, EGJ, head and neck, and bladder cancers.

Confirmed complete response in a patient with liver cancer in the Phase 1 ADP-A2AFP trial (reported as partial response in January).

Adaptimmune Therapeutics (ADAP) : GSK exercises option over SPEAR T-cell therapy program

Adaptimmune Therapeutics announces that GlaxoSmithKline (GSK) has exercised its option under 2014 license agreement

Adaptimmune will receive up to ~$61 million from GSK over the course of the transition period.

• This includes development milestones of up to ~$23 million and the option payment of ~$38 million, which also allows GSK to nominate two additional targets following completion of the transition.
• Successful continuation of development and subsequent commercialization of NY-ESO would trigger additional payments for development milestones, tiered sales milestones, and mid-single to low double-digit royalties on worldwide net sales.
• Co states, "From a financial perspective, this option exercise extends our cash runway into 2020. We anticipate the transition of NY-ESO to GSK to be completed over the coming months, after which we will focus our clinical resources on delivery and execution from our wholly-owned assets MAGE-A4, MAGE-A10, and AFP."

** charts before  ** 

 

Adaptimmune Therapeutics (ADAP) began trading on the NASDAQ on 7 May 2015

Description

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer T-cell receptors (TCRs), and produce TCR therapeutic candidates for administration to patients. The Company's target peptides are NY-ESO-1 and MAGE A-10. The Company's affinity-enhanced TCR therapeutics targets the NY-ESO-1, or NY-ESO, cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate, in patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.

Address

91 Park Drive
ABINGDON, OX14 4RY
United Kingdom

Key stats and ratios

	Q4 (Dec '14)	2014
Net profit margin	-127.81%	-2100.84%
Operating margin	-211.14%	-2376.90%
EBITD margin	-	-2335.49%
Return on average assets	-	-44.15%
Return on average equity	-	-
Employees	78